Reviewer’s report

Title: Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody

Version: 0 Date: 19 May 2019

Reviewer: Rodabe Amaria

Reviewer's report:

Please include all comments for the authors in this box rather than uploading your report as an attachment. Please only upload as attachments annotated versions of manuscripts, graphs, supporting materials or other aspects of your report which cannot be included in a text format.

Please overwrite this text when adding your comments to the authors.

Page 7 lines 31-33: the incidence of BRAF mutations in this cohort seems abnormally high considering this is a mostly mucosal/acral population, additionally the incidence of kit mutations seems low additionally, the OS seems very long if the median duration of treatment was only 2.6 months not surprising to find that the BRAF mutated patients who previously had braf/mek didn't respond well to anti pd1

I think one important thing you omitted here is that response rates are lower because you have a high percentage of mucosal melanoma patients. we know from the checkmate 067 study that mucosal patients have lower response rates/benefit from pd-1 or ipi/nivo than cutaneous patients- this should be mentioned. would be beneficial to break down response by subtype of melanoma: mucosal vs acral vs other instead of just lumping the whole population together you should add a sentence about M staging of patients, presence of brain mets, elevated LDH in the methods/patient section instead of just referring to table 1.

I don't think table 3 is all that helpful since the braf/kit status shouldn't influence pd1 response

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes
Are the conclusions drawn adequately supported by the data shown?  
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?  
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English  
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests  
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons
CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal